TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Maximum intensity of postoperative pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite outcome of hospital readmission + mortality
Endpoint domain: Mortality/survival
Primary endpoint: Composite outcome of hospital readmission + mortality + urgent visits for worsening HF
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of patients with appropriate ICD shocks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diet intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of Neuropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Progression of Neuropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Placental malaria parasitemia rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Intravascular volume measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body Composition by Magnetic Resonance Imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Blood Oxygenation Level Depend (BOLD) Signal % change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Blood pressure values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cumulative incidence of composite events (death, myocardial infarction, revascularization)
Endpoint domain: Mortality/survival
Primary endpoint: Cumulative incidence of cardiac composite events (cardiac death, target-vessel related myocardial infarction, revascularization)
Endpoint domain: Mortality/survival
Primary endpoint: Incremental Area under the glucose curve (2 hrs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants with Hemoglobin Less Than 7 g/dL or RBC Transfusion Order
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence Rate of Idiopathic Venous Thromboembolism (VTE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Protein kinetics for metabolism of proline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of Authors Who Provided Complete IPD
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Arizona Sexual Experiences Scale Male Form
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: New Sexual Satisfaction Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: rate of genotype and alleles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time for patient's survival
Endpoint domain: Mortality/survival
Primary endpoint: Number of repetitions of sit ups within 60 seconds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic parameters of VACV, ACV and CMMG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Degree of inflammation of the involved myocardium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Oxford NOTECHS scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Investigator Global Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hand Eczema Area and Severity Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Frequency and amount of opiate use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma dopamine-beta-hydroxylase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma dopamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in root thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in apical diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in endothelial dependent and endothelial-independent vasodilatation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percent Change in 28 Day Partial Seizure Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of allogeneic Red Blood Cells (RBC) units transfused intraoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in saliva osmolality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in plasma osmolality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in asthma control level score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exercise Shuttle Test (metres completed)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: In-stent late loss at 9-month
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Umbilical Artery pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psychiatric Assessment of the parents
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Voice Handicap Index - 10
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Grade-Roughness-Breathiness-Asthenia-Strain scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum phonation times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Leicester Cough Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 30 Second Chair Stand Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The Beck Depression Inventory
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: The Beck Anxiety Inventory
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rise in intraocular pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Mean Absolute Relative Difference (MARD) between G6 and YSI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Absolute Relative Difference (MARD) between Libre and YSI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Respiration Rate Accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in antibiotics prescribing behavior
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: serum citrate level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Loss of MMR gene product on tumour histology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Sedative drug amounts during colonoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Margins in specimens
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to complete recovery of muscle relaxation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Absolute Relative Difference (MARD) of Glucose Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Safety of the 3F Applicator (A3F)
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of NAFL/NASH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: patient overall satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Angiographic reduction in AVM size (volume)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Posterior Shoulder Tightness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percent of participants who aborted study participation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Shear wave elastography measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of agreement between Sleep Breathing Index Score and Apnea-Hypopnea Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Bottle use frequency
Endpoint domain: Life impact
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of Participants With Clinical Response at Test of Cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Discontinuing Study Drug Due to AEs
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Presence of myocardial ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: BOLD time series
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Structural volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of VX-984 in Combination With Pegylated Liposomal Doxorubicin (PLD)
Endpoint domain: Adverse events/effects
Primary endpoint: Modified Friedreich Ataxia Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Patient's assessment of voice severity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Vocal pitch
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in FSGS permeability factor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Patient Survival at Day-30 Post Transplant
Endpoint domain: Mortality/survival
Primary endpoint: Absence of Severe Primary Heart Graft Dysfunction in the First 24 Hours Post-transplantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Arterial Signal Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Keratinized Mucosa Width (KMW)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Soft Tissue Thickness (STT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Graft Shrinkage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adhesion area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of fatty acids in serum and erythrocyte samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Iso-BMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of patients with objective response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete regression of neovascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Adverse events (AEs) related to turoctocog alfa pegol
Endpoint domain: Adverse events/effects
Primary endpoint: Seminal elastase value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variation of spine angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variation of spine shape
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Mean Numerical Rating Scale (NRS) Score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change From Baseline in the Total Score of the Tsui Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perioperative Total Blood Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: weight loss rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Measurement of 16S rDNA gene (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Therapeutic prescription impact
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seroconversion rates of HBs-Ab after vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With TIMI Major or Minor Bleeding Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in phosphorylated-S6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of responders
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Completed course of treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of patients with adequate bowel cleansing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change of Points on Impact of event scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rate of Patients Receiving Antimicrobial Prophylaxis Within the Appropriate Timeframe Before Incision
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Eye tracking indicators
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in MDS-UPDRS Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CO2 equivalent of volatile inhaled anesthesic gases use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pregnancy in the female partner
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Incident cases of RSV bronchiolitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Survival Rate at End of 1 Year
Endpoint domain: Mortality/survival
Primary endpoint: Survival Rate at End of 2 Year
Endpoint domain: Mortality/survival
Primary endpoint: natural history of nervous system tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Cellulite Score Rated According to Cellulite Severity Scale (Dimples)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Cellulite Score Rated According to Cellulite Severity Scale (Contour)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of Occurrence of Adverse Events Based on Causality (Relationship to the Device or the Treatment)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in acceptance of probiotic supplementation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in compliance with probiotic supplementation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Patients Who Had Complete Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of women with endometrial thickness not exceeding 8mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in endometrial thickness not exceeding 3mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to corneal re-epithelization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serious adverse events occurrence
Endpoint domain: Adverse events/effects
Primary endpoint: composite of cardiovascular mortality and thrombotic cardiovascular events
Endpoint domain: Mortality/survival
Primary endpoint: Percent of responding patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Inferior Corneal Fluorescein Staining to Day 84
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Visual-Related Subscale of the Symptom Functional Scale Score to Day 84
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Neuropsychological test (Mullen Scales of Early Learning)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: functional neurological status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systemic lymphocyte activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Exogenous glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in functional status of the lumbar spine
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Lumbar pain assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective Response Rate (Complete or Partial Response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Maximum Plasma concentration at steady state (Cmaxss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of patients no longer requiring medical treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Fraction of the Dosing Interval Over Which the Concentration of Unbound Drug is Greater Than the Minimum Inhibitory Concentration (fT>MIC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Patients With Neuropathy Grade 2 or Higher
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of opioid misuse severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in WOMAC-Pain Subscale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Participants With Chronic Persistent Pain 3 Months After Surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in tumor perfusion based on DCE-MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in tumor perfusion based on DWI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Presence of splenomegaly (maximal splenic cranio-caudal length)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24 hour mean systolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pain scale POD 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain scale POD 5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-operative 3 month neuralgia
Endpoint domain: Adverse events/effects
Primary endpoint: Post-operative 6 month neuralgia
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of clinical adverse events and discontinuations due to adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of subjects with reduction in HBV DNA by ≥2 log10 or to undetectable level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decreased Pain Ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Short term outcome
Endpoint domain: General outcomes
Primary endpoint: adaptation
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: self-concept
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: pro-social behavior
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Number of Participants Reporting Risky Alcohol Use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants Reporting Weekly Alcohol Use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants Reporting Heavy Alcohol Use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: PROMIS Depression: Post-treatment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: PROMIS Depression: 3-month follow-up
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Adverse Events in the Indicated Categories
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Discontinued Due to Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients with Total Hip Replacement
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Patients with Partial Hip Replacement
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Patients with Hip Revision
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Patients with Total Knee Replacement
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Patients with Knee Revision
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in Test of Variables of Attention (TOVA) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptomatic relief of dysuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Urinary outcomes
Primary endpoint: Percent Change From Baseline in Mean Lumbar Spine Bone Mineral Density (BMD) at Month 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and mineral outcomes
Primary endpoint: Percent Change From Baseline in Mean Lumbar Spine BMD at Month 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and mineral outcomes
Primary endpoint: Percent Change From Baseline in Mean Hip Bone BMD at Month 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and mineral outcomes